Skip to content

Study · Animal study (in vivo) · rat · 2008

4 results

[Chronotropic activity of semax].

Arushanian EB, Popov AV

Eksperimental'naia i klinicheskaia farmakologiia1 Mar 2008Cited by 1 (Europe PMC)

PMID18488900 (opens in a new tab)PepBankPUB-18488900
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, chronic Semax increased the amplitude of the circadian locomotor rhythm.

    In plain wordsIn rats, long-term Semax increased the amplitude of the daily activity rhythm.

    Peptide
    Semax
    Outcome
    IncreaseAmplitude of circadian locomotor rhythm
    Study

    ratn: not reported in source

    Outcome group
    Circadian rhythm · Nervous system and cognition
    Studied dose
    Dose not stated · chronicAs given in this study (rat).

    Source sentences

    Summary
    The chronic administration of nootropic drug Semax, a peptide analog of ACTH (4-10), normalized the circadian locomotor rhythm in rats (with an increase in its amplitude
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, chronic Semax shifted the acrophase of the circadian locomotor rhythm.

    In plain wordsIn rats, long-term Semax shifted the timing of the peak of the daily activity rhythm.

    Peptide
    Semax
    Outcome
    Direction not reportedAcrophase of circadian locomotor rhythm
    Study

    ratn: not reported in source

    Outcome group
    Circadian rhythm · Nervous system and cognition
    Studied dose
    Dose not stated · chronicAs given in this study (rat).

    Source sentences

    Summary
    The chronic administration of nootropic drug Semax, a peptide analog of ACTH (4-10), normalized the circadian locomotor rhythm in rats (with an increase in its amplitude, a shift in the acrophase, and a change of the spectral characteristics) and reduced the integral chronobiological index.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, chronic Semax changed the spectral characteristics of the circadian locomotor rhythm.

    In plain wordsIn rats, long-term Semax changed the spectral features of the daily activity rhythm.

    Peptide
    Semax
    Outcome
    Direction not reportedSpectral characteristics of circadian locomotor rhythm
    Study

    ratn: not reported in source

    Outcome group
    Circadian rhythm · Nervous system and cognition
    Studied dose
    Dose not stated · chronicAs given in this study (rat).

    Source sentences

    Summary
    The chronic administration of nootropic drug Semax, a peptide analog of ACTH (4-10), normalized the circadian locomotor rhythm in rats (with an increase in its amplitude, a shift in the acrophase, and a change of the spectral characteristics) and reduced the integral chronobiological index.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, chronic Semax reduced the integral chronobiological index.

    In plain wordsIn rats, long-term Semax lowered the integral chronobiological index of the activity rhythm.

    Peptide
    Semax
    Outcome
    DecreaseIntegral chronobiological index
    Study

    ratn: not reported in source

    Outcome group
    Circadian rhythm · Nervous system and cognition
    Studied dose
    Dose not stated · chronicAs given in this study (rat).

    Source sentences

    Summary
    The chronic administration of nootropic drug Semax, a peptide analog of ACTH (4-10), normalized the circadian locomotor rhythm in rats (with an increase in its amplitude, a shift in the acrophase, and a change of the spectral characteristics) and reduced the integral chronobiological index.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.